AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 71 min read$COSM

Cosmos Health Inc. (COSM) 9M Rev ~$54.3M, Up 19%; Reaffirms 2026 >$90M

Cosmos Health Inc. reported preliminary Q3 2026 revenue of $17.4M, up 40% YoY, and 9M revenue of $54.3M, up 19% YoY. The company reaffirmed its full-year 2026 revenue outlook of over $90M, driven by growth across all core segments.

Original reporting
tradingview.com
Published Oct 7, 2026, 1:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 1:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Cosmos Health Inc. (COSM) 9M Rev ~$54.3M, Up 19%; Reaffirms 2026 >$90M — source image
Source · tradingview.com
Decision brief

The 30-second read

$COSMBullishMed
01

Why it matters

The disclosed numbers suggest accelerating growth, especially in U.S. sales, supporting a bullish stance on the stock.

02

Market read

First‑time earnings release for a micro‑cap; provides actionable data for short‑term traders.

03

What to watch

Margin data and cash flow remain unknown; growth sustainability depends on order pipeline.

Relevance 6/10Novelty 7/10Timing: pre‑market today

Background

Cosmos Health Inc. reported preliminary Q3 and nine‑month 2026 revenue, marking consecutive record quarters and reaffirming a full‑year target above $90M.

Company-level read

Ticker impact

$COSMBullishHigh confidence
Context

Preliminary nine‑month and Q3 2026 revenue figures released, reaffirming full‑year 2026 revenue guidance above $90M.

Expected impact

likely upward pressure as market prices in stronger top‑line growth and reaffirmed guidance.

Evidence & confidence

First‑time disclosure of record quarterly revenue and reaffirmed guidance provides fresh, material information for traders.

Market effects

Sector

Highlights strength in contract manufacturing and pharma distribution segments, may lift peers in health‑services space.

Regional

U.S. health‑services sector could see modest gains.

Global

Limited to U.S. micro‑cap health‑services niche.

Counterpoint

What could challenge this read

Revenue figures are unaudited; potential revisions could temper enthusiasm.

Key entities

  • Company
    Cosmos Health Inc.

    U.S. health‑services firm reporting record revenue.

Read at source← All news

Related articles

AUG 20
$COSMMed

Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities…

Cosmos Health Inc. (COSM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway · Highest Q2 and H1 revenue in Com

SEC EDGAR 8-K2 min
JUL 13
$COSMMed

Cosmos Health Accelerates Prescription Medicine Strategy with Libytec Partnership to Commercialize DIABIT-IS X in Greece

Cosmos Health (NASDAQ:COSM) said it signed a five-year agreement with Libytec to commercialize DIABIT-IS X (sitagliptin) in Greece. Cosmos, via Cana, will supply the drug, while Libytec will distribute and promote it to physicians and pharmacies. The company expects the deal to support revenue and cash-flow visibility, citing Greece’s national reimbursement system.

manilatimes.net4 min